Eiger BioPharmaceuticals, Inc.: Nasdaq/NYSE listing notice — Eiger BioPharmaceuticals receives Nasdaq bid price deficiency notice; 180 days to regain compliance

Eiger BioPharmaceuticals, Inc.

Nasdaq notified Eiger that bid price closed below $1.00 for 30 consecutive business days as of July 26, 2023.
Eiger has 180 calendar days, until Jan 22, 2024, to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant by deadline, Eiger may be eligible for another 180-day period if it meets other listing standards.
Eiger may consider a reverse stock split to cure the deficiency.
No immediate effect on listing; stock continues trading under symbol EIGR.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Eiger BioPharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

July 26, 2023, Eiger BioPharmaceuticals, Inc. (“Eiger”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying Eiger that, for the last 30 consecutive business days, the bid price for Eiger’s common stock, par value $0.001 per share (the “Common Stock”), closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Pe

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-197717

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.